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We report the case of a 15 year old girl with an 8 year his-
tory of difficult to control polyarticular ANA +ve, RF -ve,
JIA with severe right sided uveitis treated with Rituximab
based on the NICE approved regime for adult rheumatoid
arthritis.
She presented at the age of 7 years with a 6 week history
of painful arthritis involving both ankles, knees, left
elbow and left middle PIP joints. Subsequently there was
progression to include wrists, TMJs, with erosive disease in
both hips and ankles, and intermittent wheelchair use.
She was treated with 15–20 mg/m2 of Methotrexate, tried
on full dose Etanercept for 12 months, then Infliximab for
6 months, followed by Adalimumab for 6 months.
Ciclosporine was added for a 3 DMARD approach but
stopped due to hypertension. Throughout she always
required additional multiple intra-articular steroid injec-
tions and methlyprednisolone infusions (and topical
Pred Forte eye drops) to maintain her in reasonable remis-
sion. After much consideration she was treated with Ritux-
imab 1 gm by intravenous infusion repeated 2 weeks later
and sub-cutaneous methotrexate continued. Since then
she has remained in arthritis free remission for 7 months
but her uveitis is unchanged in severity. CHAQ scores fell
from 1.5 pre-treatment to 0.4 post treatment and active
joint counts fell from 5 to 0. Rituximab may be useful in
polyarticular JIA resistant to anti-TNF therapy and we rec-
ommend a drug trial for this small group of patients.
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